EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+20.95%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$6.13B
AUM Growth
+$6.13B
(+10%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-4.6%
Top 10 Holdings %
Top 10 Hldgs %
24.72%
Holding
175
New
20
Increased
64
Reduced
41
Closed
23
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$80.5M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$56.8M |
| 3 |
Xometry
XMTR
|
$47.8M |
| 4 |
Lexeo Therapeutics
LXEO
|
$40.3M |
| 5 |
monday.com
MNDY
|
$38.4M |
Top Sells
| 1 |
Korro Bio
KRRO
|
$146M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$79.8M |
| 3 |
Exact Sciences
EXAS
|
$58.1M |
| 4 |
Ascendis Pharma
ASND
|
$49.7M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$47.4M |
Sector Composition
| 1 | Healthcare | 39.38% |
| 2 | Technology | 25.83% |
| 3 | Industrials | 16.87% |
| 4 | Consumer Discretionary | 8.76% |
| 5 | Energy | 2.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
908 Devices
MASS
$211M
| $16.1M | 0.26% |
1,430,995
| – | – |
|
102
Veracyte
VCYT
$2.4B
| $15.5M | 0.25% |
564,000
-168,000
| -23% | -$4.62M |
|
103
Bruker
BRKR
$4.48B
| $15.5M | 0.25% |
210,365
| – | – |
|
104
Royalty Pharma
RPRX
$15.8B
| $15M | 0.24% |
533,975
-470,171
| -47% | -$13.2M |
|
105
Rocket Pharmaceuticals
RCKT
$363M
| $14.7M | 0.24% |
490,732
-407,268
| -45% | -$12.2M |
|
|
RCM
106
DELISTED
R1 RCM Inc. Common Stock
RCM
| $14.5M | 0.24% |
1,375,980
+640,275
| +87% | +$6.77M |
|
107
Viking Therapeutics
VKTX
$3.16B
| $14M | 0.23% |
750,000
| – | – |
|
|
INZY
108
DELISTED
Inozyme Pharma
INZY
| $13.5M | 0.22% |
3,179,837
+54,837
| +2% | +$234K |
|
109
GXO Logistics
GXO
$5.88B
| $13.5M | 0.22% |
220,170
-5
| -0% | -$306 |
|
110
Cogent Biosciences
COGT
$1.82B
| $13.1M | 0.21% |
2,232,968
+82,968
| +4% | +$488K |
|
111
Roivant Sciences
ROIV
$8.7B
| $12.8M | 0.21% |
1,143,938
-546,362
| -32% | -$6.14M |
|
112
Apellis Pharmaceuticals
APLS
$3.58B
| $12.6M | 0.21% |
+209,794
| New | +$12.6M |
|
113
IDEAYA Biosciences
IDYA
$2.32B
| $11.9M | 0.19% |
335,000
| – | – |
|
114
IDEX
IEX
$12.2B
| $11.9M | 0.19% |
54,643
-3,649
| -6% | -$792K |
|
115
Southern Company
SO
$100B
| $11.9M | 0.19% |
+169,005
| New | +$11.9M |
|
116
Intellia Therapeutics
NTLA
$1.32B
| $11.4M | 0.19% |
372,665
| – | – |
|
117
Vistra
VST
$63.1B
| $11.3M | 0.18% |
292,907
+179,769
| +159% | +$6.92M |
|
118
Verisk Analytics
VRSK
$37.2B
| $11.1M | 0.18% |
46,555
+8,674
| +23% | +$2.07M |
|
119
Revolution Medicines
RVMD
$7.62B
| $10.4M | 0.17% |
361,000
| – | – |
|
120
Encompass Health
EHC
$12.4B
| $10.1M | 0.17% |
151,644
-18,464
| -11% | -$1.23M |
|
121
Arrowhead Research
ARWR
$3.78B
| $9.59M | 0.16% |
+313,289
| New | +$9.59M |
|
122
AnaptysBio
ANAB
$583M
| $9.15M | 0.15% |
427,000
| – | – |
|
123
Sysco
SYY
$38.3B
| $8.79M | 0.14% |
120,249
-14,710
| -11% | -$1.08M |
|
124
Group 1 Automotive
GPI
$6.03B
| $8.67M | 0.14% |
28,438
+11,207
| +65% | +$3.42M |
|
125
Sarepta Therapeutics
SRPT
$1.96B
| $8.6M | 0.14% |
89,219
-33,424
| -27% | -$3.22M |
|